Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Shares Issued (2018 - 2025)

Inmune Bio's Shares Issued history spans 7 years, with the latest figure at $18.9 million for Q2 2025.

  • For Q2 2025, Shares Issued changed N/A year-over-year to $18.9 million; the TTM value through Sep 2025 reached $5.3 million, down 59.44%, while the annual FY2024 figure was $27.8 million, 3485.68% up from the prior year.
  • Shares Issued for Q2 2025 was $18.9 million at Inmune Bio, up from $5.3 million in the prior quarter.
  • Across five years, Shares Issued topped out at $18.9 million in Q2 2025 and bottomed at -$669000.0 in Q3 2022.
  • The 4-year median for Shares Issued is $5.3 million (2025), against an average of $7.4 million.
  • The largest annual shift saw Shares Issued skyrocketed 1385.54% in 2021 before it plummeted 99.8% in 2022.
  • A 4-year view of Shares Issued shows it stood at $14.9 million in 2021, then crashed by 104.49% to -$669000.0 in 2022, then soared by 2043.2% to $13.0 million in 2024, then skyrocketed by 45.38% to $18.9 million in 2025.
  • Per Business Quant, the three most recent readings for INMB's Shares Issued are $18.9 million (Q2 2025), $5.3 million (Q1 2025), and $13.0 million (Q3 2024).